The First-in-Class Drug Attacking Liver Disease at Its Rusty Roots

But none of them directly target the oxidative stress engine that drives fibrosis. They manage downstream consequences. Setanaxib is going after the factory floor.

What Setanaxib Actually Does

Imagine your liver's fibrosis process as a fire. Most current drugs are essentially hosing down the smoke. Setanaxib is trying to cut the gas line.

The drug is a first-in-class dual inhibitor of NOX1 and NOX4, two specific enzymes in the NADPH oxidase family. These enzymes are the primary producers of the ROS that drive oxidative stress in liver tissue. By blocking NOX1 and NOX4, setanaxib reduces ROS production at its source. Less ROS means less activation of the profibrotic pathways (particularly TGF-beta signaling) that tell stellate cells to start laying down scar tissue.

In preclinical models, the drug reduced stellate cell activation, cut collagen deposition, and dialed down inflammatory markers. The question was always whether that would translate to humans.

The TRANSFORM Trial: Small But Significant

TRANSFORM enrolled 76 adults with PBC who had elevated liver stiffness and either couldn't tolerate UDCA or weren't responding to it. They were randomized to one of two setanaxib doses (1,200 mg/day or 1,600 mg/day) or placebo for 24 weeks.

The primary endpoint was simple: did ALP go down?

It did. The 1,600 mg group saw roughly a 19% reduction in ALP from baseline. The 1,200 mg group dropped about 14%. Both were statistically significant versus placebo, and the effects showed up early; significant changes appeared from week 8 onward, and as early as week 4 when the dose groups were combined.

For context, ALP reduction is the accepted biochemical surrogate in PBC. It's how seladelpar and elafibranor got approved. A 19% drop at 24 weeks puts setanaxib in the conversation, though direct cross-trial comparisons are tricky.

The Fibrosis Signal: Promising, Not Proven

This is where things get more nuanced. Calliditas also measured liver stiffness using FibroScan, a non-invasive imaging tool that estimates how scarred the liver is. The results showed "positive trends" toward reduced stiffness in the setanaxib arms versus placebo.

But trends aren't statistical significance. And that distinction matters.

To be fair, detecting meaningful changes in liver stiffness typically requires a year or more of treatment. TRANSFORM only ran for six months. Earlier Phase 2a data from sicker patients (those with baseline stiffness above 9.6 kPa) had shown a roughly 3 kPa median reduction, consistent with about one stage of fibrosis improvement. So the biological plausibility is there. The 24-week window just may not have been long enough to capture it convincingly.

Notably absent from the topline results: fatigue data. Fatigue was a prespecified secondary endpoint and one of the most debilitating symptoms PBC patients face. When a company doesn't mention a secondary endpoint in its press release, experienced biotech watchers know what that usually means. It probably didn't look great.

The Safety Question Mark

Overall, the drug looked reasonably safe. Rates of adverse events and serious adverse events were similar between setanaxib and placebo. That's encouraging for a drug you'd need to take chronically.

But there's a wrinkle: more patients on setanaxib stopped treatment due to side effects than on placebo. The company hasn't fully detailed what those side effects were, and this is the kind of thing that makes analysts pause. A drug can have a great efficacy signal, but if patients keep dropping out, the real-world commercial story gets complicated.

Calliditas' Bigger Bet

Setanaxib in PBC isn't a one-off experiment. It's the centerpiece of a deliberate strategic pivot.

Calliditas built its reputation on Nefecon, a targeted-release oral budesonide for IgA nephropathy (a rare kidney disease). That drug gave the company commercial credibility and a revenue base. But one product does not a diversified pipeline make.

Enter Genkyotex. Calliditas acquired the French biotech in late 2020 and fully absorbed it by October 2021, gaining global rights to setanaxib and the entire NOX inhibition platform. The idea was elegant: one drug mechanism, multiple diseases.

Calliditas now describes setanaxib as a "pipeline in a product," and the breadth of its clinical program backs that up. Beyond PBC, the company is running a Phase 2 proof-of-concept trial in Alport syndrome (a rare genetic kidney disease), with topline data expected soon. There's an investigator-led Phase 2 in idiopathic pulmonary fibrosis. And perhaps most intriguingly, a Phase 2 trial in head and neck cancer (combining setanaxib with Merck's pembrolizumab) showed early signals of improved progression-free survival and overall survival in approximately 55 evaluable patients.

The oncology program is now listed as available for out-licensing, which tells you exactly how Calliditas is thinking: keep the rare diseases, monetize the oncology option through a partner.

A New Drug Class With Very Few Members

Setanaxib's significance extends beyond Calliditas' pipeline. The World Health Organization has formally recognized "naxibs" as a new drug class (NADPH oxidase inhibitors), and setanaxib is the most advanced member by a wide margin.

The competitive landscape is remarkably empty. A few NOX4-selective compounds are in early development for pulmonary fibrosis. Some older pan-NOX inhibitors like apocynin exist as research tools but lack the selectivity and drug-like properties needed for clinical development. That's basically it.

For liver fibrosis specifically, there is no other clinical-stage NOX inhibitor. Setanaxib doesn't just have a first-mover advantage; it has a "basically the only mover" advantage. Whether that translates into commercial opportunity depends entirely on Phase 3 execution.

What Comes Next

The TRANSFORM data are encouraging but clearly not the final word. A 14 to 19 percent ALP reduction is meaningful, and the mechanism of action is genuinely novel. But several questions remain open.

First, Calliditas needs to prove that setanaxib actually reduces fibrosis over a longer treatment period. The 24-week trends are suggestive, not definitive. Second, the discontinuation signal needs explaining. Third, the fatigue miss (or non-report) is a gap that hepatologists will notice.

The original TRANSFORM design was far more ambitious: a combined Phase 2b/3 trial with over 300 patients and 52 weeks of treatment. Calliditas scaled it down to 76 patients and 24 weeks, a pragmatic move to conserve capital and get a clean proof-of-concept. But it means a full pivotal trial is still ahead.

For investors, the readout is what analysts would call "incrementally positive": it de-risks the mechanism, adds value to the NOX platform, and justifies further investment. But it's not the kind of data that transforms (no pun intended) a stock overnight. The bigger catalysts are still coming: a Phase 3 design in PBC, the Alport syndrome readout, and any partnerships that validate the oncology angle.

For patients with PBC who are running out of options, though, the story is simpler. For the first time, someone is trying to stop the rust at its source. And the early evidence suggests it might actually work.